January/February HTB online
1 February 2013. Related: News.
The first HTB issue of 2013 is now online.
We kick off with a World Health Organisation (WHO) statement emphasising that generic antiretroviral therapy is safe and effective.
Conference coverage includes the 3rd International Workshop on HIV and Women that included a focus on hormonal contraception and a systematic review on treatment as prevention. A recent joint statement from The British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA) as well as one from the US Centers for Disease Control (CDC) on the prevention benefits of ART – both summarised in this issue – reinforce the earlier Swiss statement.
The 43rd Union World Conference on Lung Health included news on paediatric TB, including early pharmacokinetic data on second line drugs and plans for more rapid assessment of investigational ones for children. Other important TB news covered later in the issue is the FDA approval of bedaquiline for MDR TB: the first new tuberculosis drug in half a century; US funding for Xpert TB diagnostics and new UNITAID grants focus of paediatric TB.
The integrase inhibitor dolutegravir has been submitted to regulatory agencies and review articles on the complications of ART include an important study highlighting that mortality is driven more from smoking than HIV and that reduced bone mineral density may be prevelent prior to HIV infection.
Nathan Geffen takes a look at the implications of changing WHO antiretroviral guidelines to 500 threshold for starting treatment. And Richard Jeffery’s provides fascinating Basic Science updates.
Finally, please consider supporting the AllTrials campaign, reported in Other News. This demands publication of all research results to help regulators, doctors and patients to make informed decisions about treatments.
HTB supplements
Two i-Base guides have been updated and reprinted in February 2013:
Both are already online and are available free, including in bulk to UK clinics. Please order online in the regular way.